TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2884759
Drug: Hemodilution (venesection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodilution (venesection and infusion of dextran 40)
Study: 2884759
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment provided by each center
Study: 18067517
Drug: COPD training
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPD training (endurance training at 85% of VO(2max) twice weekly for 7 weeks plus daily home-based training)
Study: 16689001
Drug: Jiangtang Bushen
Normalized name: Jianghuang
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiangtang Bushen Recipe (JBR), one dose a day for 4 weeks
Study: 16689001
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (education course, dietary treatment, and conventional hypoglycemic agent)
Study: 10720511
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with zidovudine and didanosine with or without nevirapine
Study: 9178167
Drug: Riluzole 50
Normalized name: riluzole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole 50 mg daily
Study: 9178167
Drug: Riluzole 200
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riluzole 200 mg daily
Study: 8499208
Drug: Propofol (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (total dose 3.2 (SEM 0.3) mg kg‐1 h‐1)
Study: 8499208
Drug: Flunitrazepam (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (total dose 15 (2) micrograms kg‐1 h‐1)
Study: 2961355
Drug: Clodronate 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 1.6 g/day
Study: 27923381
Drug: ARTES (parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARTES (parenteral artesunate at 2.4 mg/kg at H0, H12, H24 and then once daily)
Study: 27923381
Drug: QLD (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLD (loading dose of quinine base at 16.6 mg/kg followed 8 h later by an 8-hourly maintenance dose of 8.3 mg/kg quinine base)
Study: 27923381
Drug: QNLD3 (8.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: QNLD3 (8.3 mg/kg quinine base every 8 h)
Study: 27923381
Drug: QNLD2 (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: QNLD2 (12.5 mg/kg quinine base every 12 h)
Study: 24946021
Drug: Naloxegol 25
Normalized name: naloxegol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxegol 25 mg oral dose
Study: 18780882
Drug: Conventional neurodevelopmental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional neurodevelopmental theory-based treatment (NDT) (20 sessions in 4 weeks)
Study: 16029905
Drug: High-dose pergolide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pergolide treatment (up to 12 mg/day)
Study: 9846598
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml cod liver oil daily
Study: 9846598
Drug: 2.5 ml
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 ml cod liver oil
Study: 9846598
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml cod liver oil
Study: 9846598
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml cod liver oil
Study: 9846598
Drug: 0 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 ml cod liver oil (control)
Study: 2679241
Drug: Picotamide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picotamide (3 x 300 mg tablets)
Study: 2679241
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three identical tablets)
Study: 6249875
Drug: High-dosage antithymocyte
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage antithymocyte globulin (IV regimen)
Study: 6249875
Drug: Low-dosage antithymocyte
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage antithymocyte globulin (IM regimen)
Study: 6249875
Drug: No antithymocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antithymocyte globulin treatment
Study: 31498753
Drug: Combined‐modality treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined‐modality treatment (CMT) with 2× ABVD and 20‐Gy involved‐field radiotherapy
Study: 28289111
Drug: Oral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotic (flucloxacillin) and topical placebo
Study: 28289111
Drug: Topical antibiotic
Normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antibiotic (fusidic acid) and oral placebo
Study: 28289111
Drug: Control (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (oral and topical placebos)
Study: 12355939
Drug: Postoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative oral administration of 5-FU followed by venous injection of MMC
Study: 8021763
Drug: Clarithromycin, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin, 15 mg/kg in two divided doses (n = 90)
Study: 8021763
Drug: Amoxicillin-clavulanate, 40
Normalized name: Amoxicillin-Clavulanate, 400 mg-57 mg oral tablet, chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate, 40 mg/kg in three divided doses (n = 90)
Study: 8021763
Drug: Amoxicillin-clavulanate (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate (n = 82)
Study: 31299461
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Treatment (CBT) and Wait-list Control (WLC)
Study: 25786408
Drug: Clozapine treatment
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine treatment in nonremitters after switching
Study: 21999905
Drug: Treatment Adherence
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Adherence Therapy (TAT)
Study: 19552746
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg alone
Study: 19552746
Drug: Anacetrapib 150
Normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib 150 mg co-administered with simvastatin 40 mg
Study: 11304904
Drug: warfarin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: warfarin and bucolome (300 mg once a day)
Study: 9715781
Drug: Transdermal estradiol-17beta
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol-17beta (E2)
Study: 7845815
Drug: Steroid-eluting active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-eluting active fixation lead
Study: 1092617
Drug: Dextran 70
Normalized name: Dextran 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran 70 (Macrodex) - 500 ml at operation and 500 ml on the first postoperative day
Study: 31107929
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (implants inserted without any augmentation procedures)
Study: 23608801
Drug: Modified group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified group (paralleled clipping of rectal ligament, 48 patients)
Study: 19384216
Drug: FFR‐rFVIIa (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFR‐rFVIIa (various doses)
Study: 17479208
Drug: Oral Mg
Normalized name: cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Mg citrate 300 mg/day (group A)
Study: 16020987
Drug: Voice therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice therapy techniques
Study: 9288699
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 daily plus medroxyprogesterone acetate (MPA) 10 mg, days 1-12
Study: 9288699
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 daily plus MPA 2.5 mg daily
Study: 9288699
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 daily plus micronized progesterone (MP) 200 mg, days 1-12
Study: 2852252
Drug: Lisinopril, 20
Normalized name: Lisinopril, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril, 20 to 80 mg once daily
Study: 2852252
Drug: Nifedipine retard,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine retard, 20 to 40 mg twice daily
Study: 18344432
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of blood‐derived circulating progenitor cells (CPCs) (69 +/- 14 x 10(6) CPCs)
Study: 15800267
Drug: Sunscreen application
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sunscreen application (daily application)
Study: 12055818
Drug: Praziquantel (PZQ)
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel (PZQ) chemotherapy
Study: 6360300
Drug: 2000 rad
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 rad in 10 daily fractions
Study: 24246818
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise as an adjunct smoking cessation treatment
Study: 20802206
Drug: Deep brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep brain stimulation ON with medication ON
Study: 20802206
Drug: Deep brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep brain stimulation OFF with medication ON
Study: 20802206
Drug: Deep brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep brain stimulation ON with medication OFF
Study: 20802206
Drug: Deep brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep brain stimulation OFF with medication OFF
Study: 10782658
Drug: > 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: > 0 and <= 10 g of alcohol/day
Study: 10782658
Drug: > 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: > 10 and <= 20 g/day
Study: 10782658
Drug: > 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: > 20 and <= 30 g/day
Study: 10782658
Drug: > 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: > 30 and <= 40 g/day
Study: 10782658
Drug: > 40
Normalized name: Hyrimoz Pediatric Crohn's Starter Kit Patient Weight > 40 KG
Approvals — FDA: no, EMA: no, PMDA: no
Description: > 40 and <= 50 g/day
Study: 10782658
Drug: > 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: > 50 g/day
Study: 8873656
Drug: Accelerated tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated tissue plasminogen activator (TPA) plus intravenous heparin
Study: 8873656
Drug: Streptokinase and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase and TPA plus intravenous heparin
Study: 31045669
Drug: Adductor canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adductor canal block and periarticular injection
Study: 19047294
Drug: Standard-dose induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose induction chemotherapy (cytarabine, daunorubicin, and 6-thioguanine)
Study: 19047294
Drug: High-dose induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose induction chemotherapy (cytarabine and mitoxantrone)
Study: 19047294
Drug: High-dose combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose combination (two courses)
Study: 17459189
Drug: Low-fat milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat milk with added 20 mmol/l NaCl
Study: 16425789
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg once daily for 6 weeks
Study: 12002729
Drug: 10mg Montelukast
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg Montelukast (ML) + 10mg Loratadine (LT)
Study: 1923171
Drug: No transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No transdermal scopolamine (Control)
Study: 7040956
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside infusion for 48 hours
Study: 7040956
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside infusion started within nine hours of onset of pain
Study: 7040956
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside infusion started later than nine hours of onset of pain
Study: 29368902
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution as an irrigant during surgical extraction and mouthwash for a week after extraction.
Study: 22249475
Drug: Zinc (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (40 mg twice weekly)
Study: 11709566
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (four cycles of fluorouracil, epirubicin, and cyclophosphamide)
Study: 17154437
Drug: Clonazepam test
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonazepam test formulation from Ranbaxy Laboratories Ltd (2 mg)
Study: 17154437
Drug: Rivotril from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivotril from Roche Laboratórios Ltda (2 mg)
Study: 15688960
Drug: Daily flossing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily flossing regime
Study: 12208408
Drug: Amiodarone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (300 mg over 10 minutes)
Study: 12208408
Drug: Ibutilide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide (1 mg over 5 minutes)
Study: 9803987
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg) with ferrous sulphate (300 mg)
Study: 24193079
Drug: Nondepressed Patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondepressed Patients (Clinician-reported antidepressant prescribing)
Study: 24193079
Drug: Nondepressed Patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondepressed Patients (Patient-reported antidepressant recommendation)
Study: 19644849
Drug: Golimumab 100
Normalized name: golimumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 100 mg plus MTX
Study: 19644849
Drug: Combined golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Combined golimumab groups (50 mg + MTX and 100 mg + MTX)
Study: 14665448
Drug: Dexamethasone 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 2.0 mg orally
Study: 11703573
Drug: Interferon therapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon therapy (IFN)
Study: 9380826
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment couch
Study: 7898001
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of antibiotics for treatment of the recurrence
Study: 31267277
Drug: Reflexology intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reflexology intervention (4 weekly sessions, 30-min protocol)
Study: 25424947
Drug: A/H1N1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/H1N1 vaccine formulations with varying antigen quantity (3.75 µg to 30 µg of hemagglutinin) and MF59(®) adjuvant (none, half dose, or full dose)
Study: 25424947
Drug: A single
Normalized name: Hemoccult Sensa Single Slide
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single vaccine dose containing 3.75 µg of A/California/7/2009 (H1N1) antigen with MF59 adjuvant
Study: 24360042
Drug: Modified balloon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified balloon dilatation and traditional swallowing therapy (E-stim, Mendelsohn Maneuver, supraglottic swallowing) for 3 weeks
Study: 24360042
Drug: Traditional swallowing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional swallowing therapy for 3 weeks
Study: 21827440
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg/kg (group SP2)
Study: 21827440
Drug: Propofol 1
Normalized name: propofol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1 mg/kg (group SP1)
Study: 18279736
Drug: On-treatment triglycerides
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-treatment triglycerides (TG) <150 mg/dl
Study: 18279736
Drug: Each 10
Normalized name: ClindaReach 10 MG/ML Medicated Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 10 mg/dl decrement in on-treatment TG
Study: 18279736
Drug: TG <150
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG <150 mg/dl and LDL-C <70 mg/dl
Study: 18279736
Drug: Low on-treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low on-treatment TG, LDL-C, and C-reactive protein (<2 mg/l)
Study: 16545135
Drug: Random gentamicin
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random gentamicin concentration measured 4-20 hours after administration
Study: 15023597
Drug: High meat
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High meat diet (HM) for subjects with high triglycerides (>1.5mmol/L)
Study: 7564674
Drug: Azithromycin 20
Normalized name: azithromycin 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 20 mg/kg weekly (days 1, 8, and 15)
Study: 7564674
Drug: Tetracycline eye
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline eye ointment (days 1-42)
Study: 1688482
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg of sotalol administered twice daily
Study: 1688482
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of propranolol administered 3 times daily
Study: 1688482
Drug: 320 mg
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg of sotalol administered twice daily
Study: 1688482
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of propranolol administered 3 times daily
Study: 26117466
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg loading dose (LD) of ticagrelor
Study: 26117466
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg maintenance dose (MD) of ticagrelor
Study: 23229236
Drug: Anesthetic blockage
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthetic blockage of the auriculotemporal nerve with injections of 1 ml of bupivacaine 0.5% without vasoconstrictor for 8 weeks (group 1)
Study: 23229236
Drug: Anesthetic blockage
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthetic blockage and physical therapy (massage and muscular stretching exercises) (group 2)
Study: 16690431
Drug: Iodine (131I)
Normalized name: Iodine (131I) compounds
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine (131I) metuximab injection (27.75 MBq/kg)
Study: 15066459
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of sildenafil citrate (VIAGRA)
Study: 2567579
Drug: H1 receptor
Normalized name: Histamine H1 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 receptor antagonist, levocabastine
Study: 2567579
Drug: H2 receptor
Normalized name: Histamine H2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 receptor antagonist, ranitidine
Study: 2567579
Drug: H1 and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 and/or H2 antagonists
Study: 27798730
Drug: Apatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib treatment
Study: 26295507
Drug: Hydrocortisone cream
Normalized name: Hydrocortisone Cream
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone cream
Study: 26295507
Drug: No cream
Normalized name: Oil, Multi Ingredient Topical application Oil [AVEENO CREAMY MOISTURIZING OIL]
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No cream application (Control)
Study: 15181058
Drug: Combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormone therapy (CHT) - continuous conjugated equine estrogen/cyclical micronized progesterone for 3 months
Study: 10886121
Drug: Yohimbine 22
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine 22 mg
Study: 10886121
Drug: Clonidine 0.2
Normalized name: CLONIDINE 0.2MG/24HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.2 mg + Yohimbine 22 mg
Study: 11480052
Drug: Dobell's solution
Normalized name: Dobell's Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobell's solution (control group 1, 29 patients)
Study: 11480052
Drug: Koutai solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Koutai solution (control group 2, 30 patients)
Study: 8513841
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose hamamelis PC-cream
Study: 8513841
Drug: Hamamelis cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hamamelis cream (without PC)
Study: 8513841
Drug: Chamomile cream
Normalized name: Chamomile
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile cream
Study: 8513841
Drug: Hamamelis PC-cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hamamelis PC-cream
Study: 31808686
Drug: MHBAs (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHBAs (35 mg/day)
Study: 28290272
Drug: SCP beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCP beverage (333 mg SCP) daily for 6 weeks
Study: 28290272
Drug: Control beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control beverage (0 mg SCP)